Podcasts about tnx

Tonix Pharmaceuticals Holdings CEO Dr Seth Lederman joined Steve Darling from Proactive to share encouraging preclinical results presented at the American Association for Cancer Research, highlighting the company's novel therapeutic candidate TNX-1700 for gastric cancer. In the study, a murine fusion protein (mTFF2-MSA) was tested, modeling the human fusion version TFF2-HSA currently under development as TNX-1700. Dr. Lederman explained that combining mTFF2-MSA with anti-PD1 immunotherapy significantly reduced tumor immunosuppression in animal models. Specifically, the therapy decreased immunosuppressive neutrophils and cancer-induced granulopoiesis, while stimulating CD8+ T-cell responses that helped inhibit tumor progression. The study also revealed a negative correlation between TFF2 expression and PMN-MDSC levels in gastric cancer patients, supporting the clinical relevance of TFF2 modulation in immuno-oncology. Tonix plans to continue advancing TNX-1700 as a first-in-class fusion protein therapeutic for hard-to-treat cancers. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #TonixPharmaceuticals #TNX1700 #GastricCancer #CancerResearch #Immunotherapy #PD1Blockers #AACR2025 #BiotechNews #OncologyInnovation #CancerTreatment

Tonix Pharmaceuticals Holdings has announced a groundbreaking collaborative research agreement with Makana Therapeutics, aiming to explore the potential of TNX-1500, Tonix's anti-CD40L monoclonal antibody candidate, in advancing the field of xenotransplantation—the transplantation of animal-derived organs into human patients. In an interview with Steve Darling from Proactive, Tonix CEO Dr. Seth Lederman shared details of the preclinical partnership, which will evaluate TNX-1500 in combination with Makana's proprietary human-compatible organs and cells, derived from genetically engineered pigs. The collaboration will initially focus on kidney, heart, and islet cell transplant models, with the broader objective of developing new treatment options for patients suffering from organ failure. The preclinical studies are designed to generate data to support a future Investigational New Drug (IND) application to the U.S. Food and Drug Administration, with the goal of enabling compassionate use of xenotransplantation therapies in patients who have no alternative treatment options. Makana's approach centers around genetically engineered pigs that have been modified to lack swine leukocyte antigen (SLA), a key driver of immune rejection. These animals demonstrate enhanced compatibility with human biology and offer several potential advantages over competing technologies, including high fertility rates, increased litter sizes, and robust health profiles—key factors that support scalability and commercial viability in global markets. TNX-1500 is a next-generation anti-CD40L monoclonal antibody designed to modulate immune response while minimizing the risk of thrombosis—a common side effect associated with earlier anti-CD40L agents. The drug candidate holds promise in preventing organ transplant rejection, making it an ideal component of xenotransplantation protocols. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #MPOXVaccine #Smallpox #TNX801 #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #Biopharma #ProactiveInvestors

Are you looking to save time, make money, and start winning with less risk? Then head to https://www.ovtlyr.com.What if everything you thought you knew about the market… was wrong?In this wild deep dive, we unpack the real reason everyone's panicking about the bond market—and spoiler alert: it's not what the headlines are telling you. Is China really waging economic war on the U.S. by dumping treasuries? Are interest rates about to skyrocket? And why does everyone suddenly think they're a bond market expert?This isn't your average financial news recap. This is raw, unfiltered analysis with real-time charts, real talk, and real strategies you can actually use. If you're tired of the same old recycled doom-and-gloom talking points, this video breaks it all down in plain English.Here's what you'll learn:➡️ Why “only price pays” is more than just a motto—it's a survival strategy➡️ How traders really navigate fake-out headlines and emotional markets➡️ The truth about implied volatility and why most options traders get it wrong➡️ The history lesson no one's talking about: how George Soros and Scott Bessent broke the British pound—and why it might matter again➡️ What China's treasury sell-off actually means (and what it doesn't)➡️ The quiet signal in the bond market that could tip off the next big move➡️ How to protect yourself and profit when the market makes zero senseOh, and if you're wondering what the heck TLT, TNX, and “IV crush” mean… don't worry. We'll walk you through it step-by-step. Because you don't need to be an economist to make smart trading decisions—you just need the right tools and the right mindset!

Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to discuss promising topline results from the company's Phase 1, single ascending dose trial of TNX-1500 in healthy participants. The trial evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous TNX-1500 and was designed to support dosing for an upcoming Phase 2 trial in kidney transplant recipients. Two published studies in the American Journal of Transplantation demonstrated that TNX-1500 can prevent rejection, prolong survival, and preserve graft function in non-human primate renal and heart allografts, either as a single agent or in combination with other therapies. Dr. Lederman shared that Phase 1 results showed TNX-1500 at 10 mg/kg and 30 mg/kg doses effectively blocked both primary and secondary antibody responses to a test antigen. Pharmacokinetic data suggest that monthly dosing at 10 mg/kg or higher could be effective. These findings reinforce the company's confidence in TNX-1500's potential to prevent organ transplant rejection and improve graft survival with a lower long-term toxicity burden compared to existing immunosuppressive therapies. Tonix plans to present these results to the U.S. Food and Drug Administration (FDA) in an End-of-Phase 1 meeting. Pending FDA alignment, the company will move forward with a Phase 2 efficacy study in kidney transplant recipients. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #TonixPharmaceuticals #Biotech #FDA #FDAApproval #TNX1500 #MonoclonalAntibodies #OrganTransplant #AutoimmuneDisease #MedicalResearch #PharmaNews #HealthcareInnovation

Dr. Seth Lederman, CEO of Tonix Pharmaceuticals joined Steve Darling from Proactive to share news about the company's submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for its drug TNX-102 SL, a non-opioid analgesic designed to treat chronic pain associated with fibromyalgia. TNX-102 SL demonstrated statistically significant pain reduction in two Phase 3 studies and was well tolerated by patients. Dr. Lederman highlighted that the drug was granted Fast Track designation by the FDA in July 2024, a process aimed at speeding up the review of new treatments for serious conditions that address unmet medical needs. If approved, TNX-102 SL would be the first new class of fibromyalgia medication in over 15 years, offering hope to a large patient population that has struggled with limited treatment options. The drug, designed to be taken at bedtime on a daily basis, targets the non-restorative sleep characteristic of fibromyalgia, which Tonix believes is key to alleviating the condition's widespread pain. The company has also announced it has received its first payment from the Defense Threat Reduction Agency within the U.S. Department of Defense, to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. The previously announced award is for up to 34 million dollars over five years. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #FibromyalgiaTreatment #SethLederman #NDA #FDAApproval #DrugDevelopment #BiotechNews #TNX102SL #AntiviralDrugs #PharmaNews #DODContract #ClinicalTrials #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, recently shared key findings with Steve Darling from Proactive following the company's presentations at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems in Rome. The presentations detailed the eutectic formation of cyclobenzaprine HCl and mannitol, highlighting its stability and rapid dissolution, allowing for efficient transmucosal delivery of cyclobenzaprine into the bloodstream. This innovative formulation protects the drug from interacting with the basifying agent needed for absorption, offering a more effective delivery system. Dr. Lederman emphasized the ongoing unmet need for fibromyalgia treatments, with many patients unsatisfied with current options. Tonix's lead candidate, TNX-102 SL, has shown significant potential as a once-daily bedtime treatment that could provide broad-spectrum symptom relief for fibromyalgia patients. With promising results from two Phase 3 studies, TNX-102 SL is positioned to become the first new treatment for fibromyalgia in 15 years, offering hope to millions of patients seeking better management of their symptoms. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Fibromyalgia #TNX102SL #FDAApproval #DrugDevelopment #PharmaceuticalInnovation #BiotechNews #ClinicalTrials #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, recently joined Steve Darling from Proactive to discuss the company's collaboration with Bilthoven Biologicals (BBio) to advance TNX-801, Tonix's promising vaccine candidate for mpox. TNX-801 is a live, replicating, attenuated virus vaccine based on horsepox, currently in preclinical development to prevent both mpox and smallpox. TNX-801 leverages cutting-edge technology with the potential to serve as a viral vector platform, enabling the development of recombinant versions to protect against other infectious diseases. BBio, a global leader in vaccine production, was selected by the European Union for its pandemic preparedness program, making them an ideal partner for this collaboration. Dr. Lederman shared that TNX-801 has shown remarkable results in preclinical studies, demonstrating immune protection in animal models with better tolerability compared to vaccines based on 20th-century vaccinia viruses. Specifically, TNX-801 has been shown to protect non-human primates against a lethal challenge with intratracheal Clade 1 monkeypox virus. Following a single-dose vaccination, the vaccine not only prevented clinical disease and lesions but also significantly decreased viral shedding in the mouth and lungs, suggesting strong mucosal immunity and the potential to block forward transmission. This collaboration between Tonix Pharmaceuticals and BBio represents a significant step forward in the fight against mpox and smallpox, and the technology behind TNX-801 may pave the way for future vaccines against a range of infectious diseases. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Tonix Pharmaceuticals CEO Dr Seth Lederman tells Proactive's Stephen Gunnion the first patient has been enrolled in the Phase 2 CATALYST study involving TNX-1300, a novel therapy aimed at reversing the effects of cocaine intoxication. Lederman highlighted that this study, supported by the National Institute on Drug Abuse (NIDA), is a significant step forward in addressing the urgent issue of cocaine-related emergencies, which currently lack effective direct treatments. Lederman explained that TNX-1300 works by breaking down cocaine in the bloodstream, rendering it inactive and mitigating its dangerous effects. He also discussed the previous Phase 2A study where TNX-1300 showed compelling results in reversing cocaine's impact in a controlled laboratory setting. The Phase 2B study, according to Lederman, could yield results as soon as 2025, with potential pivotal implications for the treatment's future. Lederman also touched on the broader issue of cocaine intoxication in the US, noting that it often involves mixed drugs, such as cocaine combined with fentanyl, which complicates treatment and increases risks. The interview concluded with Lederman expressing optimism about the study's progress and its potential to fill a critical gap in emergency care. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #TonixPharmaceuticals #CocaineAddiction #TNX1300 #ClinicalTrial #DrugAbuse #SethLederman #FDAApproval #PharmaNews #ProactiveInvestors #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Tonix Pharmaceuticals CEO Seth Lederman speaks with with Proactive's Stephen Gunnion about the company's accelerated efforts to develop a single-dose vaccine for Mpox, TNX-801, in light of the World Health Organization's declaration of a global health emergency. Lederman highlighted the vaccine's promising results in animal studies, which showed protection against lethal challenges with Clade 1 Mpox virus and prevention of skin lesions, potentially blocking forward transmission. As the threat of more lethal strains like Clade 1 emerges, Tonix is ramping up its development process, focusing on producing GMP material suitable for human trials. The vaccine, based on Tonix's RPV platform, is designed for rapid distribution and could play a critical role in managing the public health crisis. Lederman also discussed the potential risks associated with Clade 1's spread beyond Africa, stressing the need for quick and effective solutions. With a single dose, this vaccine could provide a durable defense against Mpox, akin to vaccines for smallpox. The company's efforts reflect the urgency of the situation and the importance of innovative solutions in pandemic preparedness. Visit Proactive's YouTube channel for more videos, and don't forget to give this video a like, subscribe to the channel, and enable notifications for future content. #TonixPharmaceuticals #MpoxVaccine #SethLederman #TNX801 #PublicHealth #WHO #Monkeypox #Biotech #Pharmaceuticals #PandemicPreparedness#ProactiveInvestors #InvestmentStrategy #ProactiveInvestors ##invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Hey Strangers, #stockmarket #stock #jobs Wall Street's stock sell-off intensified in a major way Monday as concerns mounted over the health of the US economy. The Dow Jones Industrial Average (^DJI) fell over 1,000 points. The Nasdaq Composite (^IXIC) was crushed by more than 3.4%. The S&P 500's (^GSPC) losses cascaded nearly 3% in its worst day since 2022, capping its worst start to any month since 2002. Wall Street's "fear gauge" — the CBOE Volatility Index (^VIX) — touched its highest level since the early days of the COVID-19 pandemic, before retreating. Treasury yields fell, with the benchmark 10-year Treasury yield (^TNX) hovering near 3.8%. ======================================= My other podcast https://www.youtube.com/channel/UCKpvBEElSl1dD72Y5gtepkw ************************************************** Something Strange https://www.youtube.com/watch?v=GRjVc2TZqN4&t=4s ************************************************** article links: https://finance.yahoo.com/news/stock-market-news-today-global-stock-rout-deepens-as-dow-plunges-over-1100-points-sp-500-nasdaq-sink-3-200046148.html ====================================== Today is for push-ups and Programming and I am all done doing push-ups Discord https://discord.gg/MYvNgYYFxq TikTok https://www.tiktok.com/@strangestcoder Youtube https://www.youtube.com/channel/UCe9xwdRW2D7RYwlp6pRGOvQ?sub_confirmation=1 Twitch https://www.twitch.tv/CodingWithStrangers Twitter https://twitter.com/strangestcoder merch Support CodingWithStrangers IRL by purchasing some merch. All merch purchases include an alert: https://streamlabs.com/codingwithstrangers/merch Github Follow my works of chaos https://github.com/codingwithstrangers Tips https://streamlabs.com/codingwithstrangers/tip Patreon patreon.com/TheStrangers Webull https://act.webull.com/vi/c8V9LvpDDs6J/uyq/inviteUs/ Timeline 00:00 intro 00:19 Thanks 00:55 What Talking We Talking About 03:55 Article 07:33 My Thoughts 26:32 outro anything else? Take Care --- Send in a voice message: https://podcasters.spotify.com/pod/show/coding-with-strangers/message

Tonix Pharmaceuticals CEO Seth Lederman joins Proactive's Stephen Gunnion after the company received FDA Fast Track designation for its drug candidate, TNX-102, aimed at managing fibromyalgia. Lederman expressed delight at the FDA's recognition of TNX-102, highlighting that this designation will expedite interactions with the FDA as they seek marketing approval, expected in 2025. He explained that fibromyalgia is a serious chronic pain condition affecting mostly women, with about 10 million patients in the United States alone. Discussing the market opportunity, Lederman mentioned that over 2 million people are currently diagnosed and treated for fibromyalgia, indicating a significant market potential. TNX 102 stands out in the market due to its impact on pain, sleep, and fatigue, with fewer side effects compared to existing treatments. Recent trials showed statistically significant improvements in these areas, positioning TNX 102 as a promising treatment. Tonix Pharmaceuticals is preparing a new drug application, aiming for a submission in the second half of 2024 and anticipating FDA approval in 2025. The Fast Track designation may also lead to a priority review, potentially reducing the review time to six months. For more updates and detailed insights, visit Proactive's YouTube channel, give the video a like, subscribe to the channel, and enable notifications for future content. #TonixPharmaceuticals #FibromyalgiaTreatment #TNX-102 #FDAFastTrack #ChronicPain #PharmaNews #MedicalResearch #DrugApproval #HealthcareInnovation #ProactiveInterviews #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, recently joined Steve Darling from Proactive to discuss the implications of a groundbreaking report from the US National Academies of Sciences, Engineering, and Medicine on long Covid. The report defines long Covid as a chronic condition encompassing multiple diagnosable disorders, thus paving the way for better understanding and treatment approaches. A particularly significant finding in the report is the acknowledgment that fibromyalgia can now be diagnosed in patients with long Covid, which eliminates previous diagnostic uncertainties. This development is especially beneficial for Tonix Pharmaceuticals, as the company is advancing TNX-102 SL, a drug designed to treat fibromyalgia. Dr. Lederman pointed out that this new diagnostic clarity could substantially broaden the addressable market for TNX-102 SL, which already targets approximately 10 million American adults diagnosed with fibromyalgia. Tonix Pharmaceuticals is in the final stages of developing TNX-102 SL, having received FDA Fast Track designation in recognition of its significant potential. The company has completed two statistically significant studies and is preparing a new drug application for submission. Dr. Lederman, who has nearly 30 years of experience researching fibromyalgia, emphasized the potential impact of this report on the estimated 14 million Americans suffering from long Covid. This new diagnostic criterion could enable these individuals to access effective treatments for fibromyalgia, representing a significant advancement in patient care. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #TonixPharmaceuticals, #SethLederman, #LongCovid, #Fibromyalgia, #NationalAcademies, #USScience, #TNX102SL, #DrugDevelopment, #FDA, #FastTrack, #Pharmaceuticals, #Health, #MedicalResearch, #Covid19, #ChronicIllness, #Medicine, #Healthcare, #ScientificResearch, #NewDrugApplication, #FibromyalgiaTreatment#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to share exciting news about a significant achievement for the company. Tonix Pharmaceuticals has been awarded a potential contract worth up to $34 million over five years by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense. This contract aims to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections, thereby enhancing the medical readiness of military personnel in biological threat environments. Dr. Lederman explained that Tonix's program will concentrate on the optimization and development of its TNX-4200 program. The goal is to develop an orally available CD45 antagonist with broad-spectrum efficacy against various viral families through extensive preclinical evaluation. The program is expected to establish essential physicochemical properties, pharmacokinetics, and safety attributes to support an Investigational New Drug (IND) submission, ultimately funding a first-in-human Phase 1 clinical study. The agreement with DTRA is a strategic move to address the DoD's objective of protecting U.S. Joint Forces from potential biological weapon threats. The DoD announced in December 2022 that it aims to move beyond the traditional ‘one bug, one drug' approach and is seeking broad-spectrum drugs, as predicting which viruses or how many may be deployed in a biological threat scenario is challenging. Dr. Lederman emphasized that the collaboration with DTRA underscores Tonix Pharmaceuticals' commitment to advancing medical readiness and protection for military personnel. By developing a broad-spectrum antiviral agent, Tonix aims to provide a versatile and robust solution to potential viral threats, enhancing the preparedness and resilience of the U.S. military in diverse and unpredictable biological threat environments. The TNX-4200 program's focus on creating an effective, orally available antiviral agent highlights Tonix's innovative approach to addressing complex medical challenges. The successful development of this broad-spectrum antiviral could significantly impact the way viral infections are managed in military and potentially civilian populations, offering a proactive measure against a wide array of viral threats. Tonix Pharmaceuticals continues to be at the forefront of medical innovation, dedicated to developing cutting-edge solutions that meet the evolving needs of the healthcare and defense sectors. The support from the DoD through this substantial contract is a testament to the potential and importance of Tonix's TNX-4200 program in safeguarding the health and readiness of military personnel against biological threats. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #BroadSpectrumAntiviral, #USDepartmentOfDefense, #BiologicalWarfare, #DrugDevelopment, #ImmuneSystem, #SyntheticBiology, #VirusResearch, #InfectiousDisease, #R&D, #FrederickMaryland, #PharmaceuticalInnovation, #HealthcareTechnology, #Biotech, #MedicalResearch, #DefenseContract, #AntiviralAgent, #Healthcare, #PandemicPreparedness, #ScientificResearch#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Durante 2023 ha ocurrido un fenómeno particular: el TLT, que representa a los bonos estadounidenses a 20 años, ha registrado una estrepitosa caída especialmente desde mediados de año. Aún no se recupera. Los bajistas le apostaron a su caída y al hacer shorts con este activo provocaron su desvalorización. En cambio, con el TNX, es decir con los bonos a 10 años, ha ocurrido todo lo contrario, aunque en los primeros días de noviembre tendieron a inclinarse en dirección bajista en lo que se interpretó como una actitud común del mercado que está expectante sobre cómo evoluciona la situación económica.

Die letzte Podcast-Folge, in der wir eure K-Pop-Songempfehlungen angehört haben, ist tatsächlich schon sehr lang her. Das holen wir nun nach, bevor es in die Sommerpause geht! Wir haben euch in unserer Instagram-Story nach Songs gefragt und haben richtig viele Banger von euch erhalten. Seid dabei, wenn wir von Taemin, B.I, NewJeans oder TNX vom Hocker gehauen werden! Welches Lied war euer Favorit?Hier findet ihr die aktualisierte Spotify-Playlist, in der wir alle Songs dieser Reihe aufgelistet haben!Für uns geht es nun in eine lange Sommerpause! Wir wünschen euch einen wundervollen & erholsamen Sommer. Bleibt gesund und hydrated, ihr Lieben! Wir hören uns vermutlich im Oktober wieder. Solltet ihr uns vermissen, dann könnt ihr gern zu Patreon rüberhüpfen, um unsere Bonusfolgen anzuhören! We purple you

In this episode, discuss celebrities getting favoritism at Bruno Mars concert, the TXT and Jonas Brothers collaboration, Ph-1Harmony signing with CAA, Seventeen's Vernon appointed global ambassador position with Kenzo, & Blackpink's Jennie part in the new controversial song with the Weekend/Lily-Rose Depp. I speak on the validity of BTS's rumors on Jimin, Jungkook, and BTS enlisting by end of 2023 and what members of BTS has been up to for the week. I talk about comeback information for New Jeans & Itzy, and Ateez's new found success with their latest song. I also mention Stray Kids, XG, TNX, Lapillus, VAV, Kang Daniel, NCT Dream, EXO, DKB, LUN8, Taeyondo (from NCT), and Hoshi (from Seventeen)! --- Support this podcast: https://podcasters.spotify.com/pod/show/thatkpoptalk/support

One of the questions Tami gets most often is, “When are we going to have new fibromyalgia treatment options?” With only three FDA-approved fibromyalgia medications, many of us are on the alert for new options to address our symptoms better. To answer that question, Tami invited Dr. Seth Lederman, CEO and founder of Tonix, to talk about the fibromyalgia medication currently in phase three trials, TNX-102 SL. Dr. Lederman has dedicated his career to fibromyalgia research and has worked on this drug for almost 25 years. Today he's sharing all the details about how TNX-102 SL could help fibromyalgia patients and walking us through the process of developing a new medication. In this conversation, Tami and Dr. Lederman talk about the process of creating a new medication and the FDA approval process, the significant challenges in the medication creation process, TNX-102 SL - the new fibromyalgia medication Dr. Lederman has been working on for almost 25 years, how TNX-102 SL is different and improved over Flexeril, the importance of improving sleep quality for fibromyalgia patients, the benefits of improved sleep quality, unrefreshing sleep in fibromyalgia patients and how it relates to the pain perception system, the current phase three trial of TNX-102 SL and how you can find out more, next steps after the successful completion the current study, preliminary results showing the positive effects of TNX-102 SL on the quality of life of fibromyalgia patients, the overlap between long COVID and fibromyalgia, the varied factors that can lead to the development of fibromyalgia, a new drug under development for depression that could also have activity in fibromyalgia, positive progress in fibromyalgia research and treatment, Dr. Lederman's message for you, and more.     Note: This episode is not meant to be medical advice. Every person and every situation is unique. The information you learn in this episode should be shared and discussed with your own healthcare providers. To learn more about the resources mentioned in this episode, visit the show notes. For daily doses of hope, inspiration, and practical advice, join Tami on Facebook or Instagram. Need a good book to read? Download Tami's books for free. Ready to take back control of your life and health? Schedule a complimentary consultation with a Certified Fibromyalgia Coach®.

TNX drop the song of the summer, NCity is up in flames yet again, and BTS celebrate their 10th year anniversary in the best way they know, by dropping the emo af song. Listen as we discuss what happened in the KPOP world this past week!Tune in every Tuesday for a new episode and don't forget to follow our social media and let us know what you think.Time stamps:1:59 - NCT chaos9:05 - Big Naughty under fire11:28 - Krazy K-Pop super concert in NYC13:27 - KCON 202316:43 - NCT Taeyong - SHALALA22:02 - TNX - Kick It 4 Now30:43 - P1Harmony - JUMP38:16 - Fromis_9 - #menow40:04 - BTS - Take Two48:09 - SHINee - The Feeling51:44 - Songs of the WeekListen here!Apple: https://podcasts.apple.com/us/podcast...iHeartRadio: https://www.iheart.com/podcast/269-no...Spotify: https://open.spotify.com/show/4OL4qPj...This week's playlist: https://open.spotify.com/playlist/5XaqqWd4k7DnBFkVoH7wsH?si=10a92a446f1847ebwww.twitter.com/NYAFangirlswww.twitter.com/HollaItsCarowww.twitter.com/heyitsteeteewww.twitter.com/deekaydiwww.twitter.com/HollaItsCyn

In this episode, I discuss SM Entertainment's artists switching to Weverse platform, G-Dragon leaving YG, Jennie's Idol & Chanel controversy, & EXO & SM Entertainment's ongoing feud. I discuss BTS's Jungkook's actual release date of his upcoming album, Suga's controversial MV with Halsey, and what the rest of BTS's members been up to during the 10th Anniversary Festa. I also mention: Twice's Jihyo, TNX, Enhypen, and P1Harmony. --- Support this podcast: https://podcasters.spotify.com/pod/show/thatkpoptalk/support

658 Fed to reassess ‘fast and furious pace of rate hikes' after bank failures: StrategistScroll back up to restore default view. Dani Romero Dani Romero·Reporter Mon, March 13, 2023 at 3:05 PM CDT In this article: USB -10.04% BAC -5.81% ^DJI -0.28% ^TNX -4.87% ^IXIC +0.45% ^GSPC -0.15% U.S. stocks finished Monday mixed as volatile trading gripped Wall Street after federal banking regulators took aggressive actions to stem the fallout of Silicon Valley Bank's failure

658 Fed to reassess ‘fast and furious pace of rate hikes' after bank failures: StrategistScroll back up to restore default view. Dani Romero Dani Romero·Reporter Mon, March 13, 2023 at 3:05 PM CDT In this article: USB -10.04% BAC -5.81% ^DJI -0.28% ^TNX -4.87% ^IXIC +0.45% ^GSPC -0.15% U.S. stocks finished Monday mixed as volatile trading gripped Wall Street after federal banking regulators took aggressive actions to stem the fallout of Silicon Valley Bank's failure

(토) 웬디의 영스트리트 - 영스스쿨 / TNX(우경준, 장현수, 은휘) - 2023.2.25

왔어요 with TNX

(일) 컬투쇼 - 하드를 털어라 + 고막을 털어라 (TNX(최태훈, 우경준)) - 2023.2.19

Crude oil's (/CL) weakness continues to start 2023. Dan Deming discusses the reasons behind the weakness in crude to start the year. He also talks about today's metals movers. He then goes over how treasury yields, FVX, TNX, and TYX, are all falling. Tune in to find out more about the stock market today.

Are interest rate buying into the hawkish tone of policymakers like Jerome Powell and the rest of the Federal Reserve? "I am watching the TNX spread from a technical analysis perspective. When interest rates invert that is a sign that we could have a recession. However, a recession with 3% unemployment is odd. There is an impact of a hawkish tone on interest rates. At some points, rates will have to go higher to attract money to continue to finance the debt in the United States," says Chris Robinson.

I'm not so sure that this is a dip yet, says Scott Bauer. He previews Powell's announcement and discusses treasury yields FVX, TNX, TYX. He also talks about expectations for the bond market. He then notes that the U.S. dollar (/DX) futures have fallen 4% this month. Tune in to find out more about the stock market today.

New Jeans, NMixx, TNX!! Today we are talking about the rookie/debut groups of 2022 and who we think has the potential to break out!! And, PS....we recorded this on the heels of BTS announcing their military enlistment, soooo Maya has her sad moment too lol!!

We cannot just look at one data point and determine we made a pivot, says Scott Bauer. He discusses what's next for treasuries FVX, TNX, TYX, after the recent rally. He talks about the chances that this bear market rally could last. He then goes over the signs that the dollar (/DX) is oversold. Finally, he notes what the yield curve means for the markets. Tune in to find out more about the stock market today.

We are halfway back to the S&P 500 (SPX) recent high, says Chris Robinson. He talks about how this gives investors time to reset themselves. He also talks about how important it is to not let your emotions get in the way of your trading decisions. He then looks at treasury yields FVX, TNX, and TYX. Finally, he mentions recent moves in the pound (/6B) as the UK's political turmoil calms. Tune in to find out more about futures today.

Will The Fed Signal An End To Rate Hikes? He discusses the Fed's policy after Friday's Wall Street Journal report. He talks about how the Fed's Daly says more hikes are necessary to reach a restrictive stance. He then examines the rise in treasury yields FVX, TNX, and TYX. He also goes over what's next in the Fed's rate hike plan.

Earnings are still surprising to the upside, says Michael Purves. He discusses the outlook and expectations for earnings season. He also talks about what rising yields means for investors, highlighting FVX, TNX, and TYX. Next, he asks is it time to sell equity volatility? Then, he looks at the latest bond market activity. Finally, he goes over pricing in a possible Fed pivot as inflation remains elevated. Tune in to find out more about the stock market today.

It's more about the signaling, than the actual action itself, says Jim Bianco. He discusses the Fed's policy after Friday's Wall Street Journal report. He talks about how the Fed's Daly says more hikes are necessary to reach a restrictive stance. He then examines the rise in treasury yields FVX, TNX, and TYX. He also goes over what's next in the Fed's rate hike plan. Tune in to find out more about the stock market today.

Negative demand shock/economy is very clearly on the horizon, says Zachary Hill. He previews the next FOMC meeting which takes place Nov. 1-2 and what Fed's next rate hike will look like. He also notes that he likes dividend payers, but is avoiding cyclicality. He then goes over how to price in the Fed's next rate hike, highlighting treasury yields FVX, TNX, and TYX. He then forecasts the market performance into the year's end. He also talks about the jobless claims for the week of Oct. 15, as well as which sectors could outperform in a down market. Tune in to find out more about the stock market today.

Aggressive rate hikes work by reducing demand, but can't fix supply issues, says Caleb Tucker. He discusses fixed income opportunities to consider, highlighting treasury yields FVX, TNX, and TYX. He also talks about how long the Federal Reserve's rate hike plan will last. He then goes over market volatility noting that the markets have a wide range of outcomes internationally, especially in Europe. Tune in to find out more about the stock market today.

All indices are up as they held onto their rally.10 of 11 S&P 500 sectors are in the green. As for commodities, crude oil (/CL) closed a little lower, natural gas (/NG) is up almost 13%, and gold (/GC) rose but fell a little into the close. Bitcoin (/BTC) made its first big move to the upside in a while and the TNX is up about 3%. There is strength in the energy sector, consumer discretionary, and tech with names like Apple (APPL), Amazon (AMZN), Tesla (TSLA), and Exxon (XOM) performing the best. There is weakness in utilities, real estate, and consumer staples particularly in American Tower Corp (AMT), Coca-Cola (KO), Colgate (CL), and Duke Energy (DUK). Tigress reiterated a strong buy rating on Meta (META) and Boston Beer (SAM) was downgraded by RBC Capital. International trade in goods and services came in with a slightly larger than expected trade deficit and jobless claims are holding steady.

U.S. natural gas (/NG) got crushed last week, says Bill Baruch. He discusses how the dollar (/DX) is strong to start the week. He also compares it to euro currency. He then previews the FOMC minutes which will be released on Wednesday. He talks about how the FOMC seems to be continuing to press on with rate hikes. He then goes over the ten year yield (TNX) and how it has come off. Tune in to find out more.

(토) 웬디의 영스트리트 - 영스스쿨 / TNX(최태훈, 천준혁, 오성준) - 2022.7.2ART19 개인정보 정책 및 캘리포니아주의 개인정보 통지는 https://art19.com/privacy & https://art19.com/privacy#do-not-sell-my-info 에서 확인하실 수 있습니다.

(일) 컬투쇼 - 게시판을 털어라, 게털! (곽범, 이창호) + 고막을 털어라 (TNX(우경준, 오성준)) - 2022.6.12ART19 개인정보 정책 및 캘리포니아주의 개인정보 통지는 https://art19.com/privacy & https://art19.com/privacy#do-not-sell-my-info 에서 확인하실 수 있습니다.

There are times where the best trade is sitting on your hands, says Huw Roberts. He monitors recent trends in credit spreads, highlighting treasury yields FVX, TNX, and TYX. He also talks about factors that impact the high yield market, underlining the iShares Trust iBoxx ETF (HYG). He then goes over the market impact of the Fed's monetary policy. Tune in to find out more.

This week, we're bringing you a bit of a deeper Mini Dive into P Nation's first boy group, TNX! We introduce the members, discuss our first impression of their debut EP Way Up, and curse both PSY and Penomeco for giving us yet another excellent group with great songs to care about. Follow us on our social media! Twitter: https://twitter.com/seouldivepod Instagram: https://www.instagram.com/seouldive

Steve Penny, Publisher of The SilverChartist Report, shares key charts for Platinum, Gold, Silver, Commodities versus Stocks, Junior Silver Miners and the (TNX) 10-year treasury yields.

(토) 러브게임 - 2022년 5월 28일 방송분 (유재필, TNX(태훈, 경준, 성준))ART19 개인정보 정책 및 캘리포니아주의 개인정보 통지는 https://art19.com/privacy & https://art19.com/privacy#do-not-sell-my-info 에서 확인하실 수 있습니다.

Summer is just around the corner as we cover the debut of TNX, Yerins solo debut, and the return of GOT7! As always, the Crew keeps you up to date with all the recent Kpop News/Events. And you know we gonna get hype with the State of the Nation!!! Links ◆Email - sojutalkpodcast@gmail.com ◆Discord - discord.gg/sojutalk ◆Patreon - patreon.com/sojutalk

Futures to the downside means rates to the upside. Chris Robinson reviews the financial markets as many are currently selling off. He and Ben Lichtenstein discuss the charts for the 30-year treasury index (TYX), the 10-year treasury index (TNX), 30-year treasury bond futures (/ZB), and 10-year treasury note futures (/ZN). They talk about how its important to watch all currencies like the British Pound (/6B). They also discuss how the U.S. dollar (/DX) is the most crucial to watch during this sell-off. Tune in to find out more.

Investors are skeptical that the Fed can quell inflation, says Katie Binns. She discusses the reasons for the continuing upward march in yields, highlighting the FVX, TNX, and TYX. She also talks about areas of opportunity in the bond market as recession fears still loom. She then goes over the outlook for treasuries as the Fed raises rates. Tune in to find out more.

00:00 - Good Morning 00:07 - My Mother 01:29 - Omer/Emails/Pictures 04:14 - Sponsors 06:48 - Amud Beis 09:42 - Amud Aleph 36:03 - Amud Beis 49:14 - Have a Wonderful Day -- Today's shiur is sponsored לענ הרב זכריה שמעון הכהן וואלערשטיין זצ׳ל By his kids & Ahron Fraiman Lzchus continued parnasah, siyadta dishmaya, and hatzlacha to R Eli! & the Wolkenstein family אם אין קמח, אין תורה; אם אין תורה, אין קמח & By the Lock and Lebovic families Lakewood NJ, because Torah is the best segulah! & as a Zechus to Aaron's Hatzlacha And to YOU (the magid shiur) and the video editor for hatzlacha in continuation & not missing a shiur & לז'נ ר' אברהם יצחק בן בנימין & Anonymously לע״נ חיה בת יוסף & Anonymously As a HaKaras HaTov to Hashem and as a zechus for continued health and bracha & the Boyer Family: לעילו נשמת ר׳ אליהו ז״ל בן ר׳ אברהם נ״י Eli Weinberg A”H A dear family friend who suddenly passed away at the age of 59, he loved MDY and was proud to be a part of this amazing daf yomi shiur & Yossi Kleins Bday! Tnx for pushing me to do the Daf Yankel from Fidelity/Cardknox & Yacov and Malka Slatus For our son, Alter Yeshaya ben Malka Chaya, undergoing a medical procedure today & The Austein Grandchildren L'N Mr. Leo Schachter; Yitzchak Aryeh Ben Menachem Mendel -- Turning of the daf Sponsored by Moshie Horn in honor of the gold star, Moti Donut & Anonymously As a zechus for Moshe Yakov ben Shoshana in both ruchnius and gashmius

Crude oil (/CL) slips below $100 per barrel. Scott Bauer discusses the movement in crude oil and gold (/GC), as gold price are falling for the third straight session. He also previews the FOMC announcement tomorrow and talks about treasury yields FVX, TNX, and TYX. Tune in to find out more.

Crude oil (/CL) prices slid below $100 in today's session. Chris Robinson discusses how gold (/GC) and other metals futures slid today in Monday's session. He also talks about how Covid lockdowns in China impact crude oil prices and how the10-Year treasury yield (TNX) hits new 52-week high. Tune in to find out more.

U.S. stock futures are falling as treasury yields steady. Chris Robinson, Managing Director at TJMM Institutional Services, discusses this, highlighting treasury yields FVX, TNX, and TYX. He also talks about movement in US Dollar Index Futures (/DX). He then goes over how the NASDAQ-100 fell about 4.5% for its worst week since February 2021. Tune in to find out more.